Clinical trial of acetylcysteine effervescent tablets in the treatment of chronic obstructive pulmonary disease
10.13699/j.cnki.1001-6821.2018.07.008
- VernacularTitle:乙酰半胱氨酸泡腾片治疗慢性阻塞性肺疾病的临床研究
- Author:
Yu-Min CHI
1
;
Qing-Guo DI
;
Min LI
;
Guang-Chao HAN
;
Xin ZHANG
;
Jun-Feng DU
;
Bao-Hua SUN
Author Information
1. 沧州市中心医院呼吸科
- Keywords:
acetylcysteine effervescent tablet;
chronic obstructive pulmonary disease;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(7):763-766
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of acetylcysteine effervescent tablets in the treatment of chronic obstructive pulmonary disease (COPD).Methods One hundred and seventy-four patients with COPD were randomly divided into control and treatment groups with 87 cases per group.Control group was treated with bronchial diastolic,anticholinergic,β2 receptor agonist and glucocorticoid,and so on.Treatment group was given acetylcysteine effervescent tablets 600 mg per time,bid,orally,on the basis of control group.Tow groups were treated for 4 weeks.The clinical efficacy,lung function,the levels of interleukin-4 (IL-4) and IL-6 in serum and induced sputum,serum oxidative stress indexes and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 91.95％ (80 cases / 87 cases) and 77.01％ (67 cases / 87 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:the forced expiratory volume in one second were (1.89 ± 0.21) and (1.47 ± 0.18) L,forced vital capacity were(2.45±0.17) and (2.21±0.12)L,serum IL-4 were (0.93±0.07) and (1.17±0.16)ng·L-1,serum IL-6were (18.44 ±2.32) and (33.98 ±3.58)ng · L-1,induced sputum IL-4 were (1.61 ±0.22) and (2.15 ±0.27)ng · L-1,induced sputum IL-6 were (65.85 ± 11.34) and (82.18 ± 17.74)ng · L-1,serum malondialdehyde were (633.23 ± 76.85) and (715.46 ± 84.36) μmol · mL-1,reactive oxygen species were (49.78±6.35) and (62.77 ± 8.49)U · mL-1,superoxide dismutase were (261.15 ± 25.47) and (218.83 ±24.34)U · mL-1,glutathione peroxidase were (29.95 ±3.07) and (20.74 ±2.16) μmol · L-1,with significant differences (all P ＜ 0.05).The adverse drug reactions of two groups were stomach upset,insomnia,headache and hand tremor,and there was no significant difference on the incidence of adverse reactions in treatment and control groups (10.35％ vs 6.90％,P ＞ 0.05).Conclusion Acetylcysteine effervescent tablets have a definitive clinical efficacy in the treatment of COPD,which can improve the lung functions,reduce the levels of IL-4 and IL-6 in serum and induced sputum,inhibit oxidative stress response,without increasing the incidence of adverse drug reactions.
